Program
Atorvastatin
Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.
Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.
Drug pageAtorvastatin: every studyMany companies study it; this page follows only the 105 they lead. All 640 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 290 open or running | phase 4since Aug 30, 2005 | Aug 25, 2005 | none ahead |
| Organonits history only | 200 open or running | phase 4since Apr 1, 2008 | Sep 23, 2004 | none ahead |
| Pfizerits history only | 160 open or running | phase 4since Sep 6, 2005 | Aug 22, 2005 | none ahead |
| Chong Kun Dang Pharmaceutical | 60 open or running | phase 4since Nov 16, 2009 | Nov 16, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 60 open or running | phase 1since Jul 18, 2012 | Jul 18, 2012 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Dec 15, 2011 | Dec 11, 2006 | none ahead |
| Astellas Pharmaits history only | 30 open or running | phase 4since Dec 5, 2006 | Dec 5, 2006 | none ahead |
| Daiichi Sankyoits history only | 30 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| Midas Pharmaits history only | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Dec 20, 2011 | Dec 20, 2011 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Sep 21, 2012 | Sep 21, 2012 | none ahead |
| Clinical Research Managementits history only | 10 open or running | phase 2since Mar 1, 2015 | Mar 1, 2015 | none ahead |
| Cumberland Pharmaceuticalsits history only | 10 open or running | phase 2since Jul 19, 2018 | Jul 19, 2018 | none ahead |
| Daewon Pharmaceuticalits history only | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| Dr. Md. Alimur Rezaits history only | 10 open or running | phase 4since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Huons Globalits history only | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Jeil Pharmaceuticalits history only | 10 open or running | phase 1since Mar 5, 2018 | Mar 5, 2018 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 10 open or running | phase 3since Apr 29, 2021 | Apr 29, 2021 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 9, 2009 | Sep 9, 2009 | none ahead |
| Samil Pharmaceuticalits history only | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: Parexel, Pharma Medica Research, Merck, Regeneron Pharmaceuticals, MDS Pharma Services, Celerion, Sanofi and Basilea Pharmaceutica International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 16, 2009First study: phase 4 study in DyslipidemiasFirst studyNCT01029522 · 244 enrolled
- Apr 25, 2013Phase 1 study in Essential HypertensionNCT01842256 · 24 enrolled · Korea, Republic of
- Feb 16, 2014Phase 1 study in DyslipidemiasNCT02066207 · 30 enrolled · Korea, Republic of
- Oct 30, 2014Phase 1 study in HealthyNCT02288338 · 36 enrolled · Korea, Republic of
- Mar 25, 2015Phase 1 study in HealthyNCT02422030 · 30 enrolled · Korea, Republic of
- Nov 27, 2016Phase 2 study in DyslipidemiasNCT02977065 · 62 enrolled · Australia
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
All 6 Chong Kun Dang Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02977065Dyslipidemias · Australia | 2 | Completed | Dec 30, 2017 | 62 |
| NCT02422030Healthy · Korea, Republic of | 1 | Completed | Mar 22, 2015 | 30 |
| NCT02288338Healthy · Korea, Republic of | 1 | Completed | Feb 2015 | 36 |
| NCT02066207Dyslipidemias · Korea, Republic of | 1 | Completed | Apr 7, 2014 | 30 |
| NCT01842256Essential Hypertension · Korea, Republic of | 1 | Completed | May 2013 | 24 |
| NCT01029522Dyslipidemias | 4 | Completed | Oct 2008 | 244 |
How it is read
Names in the registry
- “Atorvastatin”, 95 entries
- “atorvastatin”, 36 entries
- “Atorvastatin 20 mg”, 3 entries
- “Comparator: atorvastatin”, 3 entries
- “Atorvastatin 10 mg”, 3 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 48 studies
- Dyslipidemias, 15 studies
- Hyperlipidemias, 11 studies
- Diabetes Mellitus, Type 2, 9 studies
- Cardiovascular Diseases, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.